Autologous Stem Cell and Non-Stem Cell Based Therapies Market Driven by Growing Demand from North America, Asia Pacific| Size, Share, Demand and Key Player Analysis by 2026
Autologous stem-cell transplantation (also known as autogeneic, autogenic, or autogenous stem-cell transplantation or auto-SCT) is the autologous transplantation of stem cells, where the undifferentiated cells or stem cells (cells from which other types of cells develop) are derived from a person, accumulated, and given back to the same person later. Even though it is most often executed by means of hematopoietic stem cells (antecedent of cells that forms blood) in hematopoietic stem cell transplantation, in some cases cardiac cells are used productively to fix the damages due to heart attacks. Stem cell transplantation are of two types such as autologous stem-cell transplantation and allogenic stem cell transplantation. In the later, the recipient and the donor of stem cells are different people.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/523
In allogeneic transplants, stem cells are taken from a donor, whose cell type matches closely with the patient’s cell type. The best donor in allogenic stem cell transplantation include immediate family member, generally brother or sister. If the patient do not have a match in his/her family, a donor may be found from the public. This is often called a MUD or matched unrelated donor transplant. This type of transplant (MUD) is generally riskier.
Increasing prevalence of diabetes and cancer, across all age groups globally are expected to drive the market growth over the forecast period. For instance, according to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for around 9.6 million deaths in 2018. Furthermore, increasing geriatric population is another driver, which is expected to fuel growth of the market over the forecast period. For instance, according to the World Population Prospects 2019 revision, the number of people aged 80 years or over is expected to triple from 143 million in 2019 to 426 million in 2050.
Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/523
However, factors such as complications and risks associated with the treatment, which includes diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications are expected to hamper growth of the market over the forecast period.
Increasing prevalence of cancer is expected to drive the autologous stem cell and non-stem cell based therapies market
According to a report by the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone. Moreover, it was also noted that around 595,690 people were reported to die from cancer in the same year. Autologous stem cell and non-stem cell based therapies is likely to become one of the preferred treatment for cancer. As the prevalence of cancer is rising at a considerable rate, the market is likely to grow over the forecast period.
North America, followed by Europe accounted for the major share of the autologous stem cell and non-stem cell based therapies market. This is attributed to minimization of risks related with the treatment. Moreover, demand for these treatments is high due in North America to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not need an outside donor, therefore the treatment is less infectious and convenient. These factors are expected to boost growth of the market in North America. However, Asia Pacific is expected to witness significant growth over the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Growing healthcare infrastructure as well as increasing collaboration and acquisition by market players in this region are also expected to drive growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific. For instance in January 2018, Vericel Corporation entered into a licensing agreement with Innovative Cellular Therapeutics (ICT) for development and distribution of autologous stem cell based therapy products such as MACI, Epicel, ixmyelocel-T and Carticel in Greater China, South Korea, Singapore, and other countries in the region.
Key players in the global autologous stem cell and non-stem cell based therapies market are focused on investing heavily in their research and development activities, so as to gain an upper hand in the market. Some of the major players operating in the market include Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/523
Key players operating in the market has robust pipeline of autologous stem cell and non-stem cell based therapies, which is expected to drive the market growth over the forecast period. For instance in November 2019, Caladrius Biosciences (previously known NeoStem, Inc) announced positive results of CD34+ cell therapy CLBS16 from the ESCaPE-CMD Trial as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women.
Moreover, major players in the industry are investing in the development of innovative and new products, in order to strengthen their position in autologous stem cell and non-stem cell based therapies market. For instance in February 2018, MEDIPOST announced that it received the U.S. Food and Drug Administration approval for its stem cell-based Alzheimer’s disease drug, NEUROSTEM for clinical trials.
Autologous stem cell and non-stem cell-based therapies market Taxonomy
On the basis of application, the global autologous stem cell and non-stem cell based therapies market is classified into:
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Cancer and Autoimmune Diseases
- Skin Transplantation
- Infectious Disease
On the basis of region, the global autologous stem cell and non-stem cell based therapies market is classified into:
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire